Oscar Health Inc (NYSE: OSCR) soared roughly 25% on Monday morning following reports that the White House will soon announce a two-year extension on Affordable Care Act (ACA) subsidies
According to Politico, the administration’s upcoming healthy policy framework will include new income caps and minimum premium payments, aiming to prevent steep cost increases for enrollees
Despite a massive surge today, Oscar Health stock remains down more than 30% versus its recent high.
Why Oscar Health stock soared on ACA extension news
The extension of enhanced ACA subsidies is undeniably positive for OSCR shares.
The company’s business model is tightly linked to the availability of government tax credits, which help lower- and middle-income consumers afford coverage.
By extending subsidies for two more years, the White House is effectively ensuring that Oscar retains access to a larger pool of customers who might otherwise drop coverage due to affordability concerns.
According to Scott Blackley, the firm’s chief of finance, brokers already know which members would be impacted by subsidy changes, meaning Oscar Health can quickly reach out to retain and attract enrollees if the credits continue.
This policy stability reduces near-term uncertainty and supports the company’s revenue outlook.
For investors, subsidy extension provides a temporary safety net that could prevent a sharp decline in membership and stabilise top-line growth.
But it remains risky to own OSCR shares
Despite the policy tailwind, Oscar Health’s fundamentals remain rather concerning.
The NYSE-listed firm has yet to demonstrate consistent profitability, which makes it hard to justify its current valuation.
Investors must practice caution on businesses that rely heavily on government programs without showing sustainable earnings power.
Additionally, Oscar Health shares remain below their 100-day moving average – indicating today’s rally may lack momentum. It signals investor sentiment is still cautious, even after a sharp surge on Monday.
Without a clear path to profitability, OSCR’s upside appears limited.
For 2026, investors will likely demand more than subsidy-driven optimism; they’d want evidence of durable margins and operational efficiency before committing capital.
History warrants trimming exposure to Oscar Health
Investors should also note that historically, OSCR stock has struggled in December, losing more than 10% on average over the past four years during that month.
This further raises doubts about whether the rally on Nov. 24 can be sustained through the end of this year.
Finally, insider activity also paints a negative picture: in the second half of 2025, executives have predominantly sold shares (not even a single buy transaction recorded since June).
What it signals is a lack of insider confidence in Oscar Health Inc’s future prospects and valuation upside.
And if those closest to the New York headquartered firm aren’t willing to bet on it, why would you?
The post Oscar Health stock: why Obamacare extension isn’t a strong enough reason to own it appeared first on Invezz
